Model of Chemotherapy-induced Myelosuppression with Parameter Consistency Across Drugs
Overview
Affiliations
Purpose: To develop a semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression through drug-specific parameters and system-related parameters, which are common to all drugs.
Patients And Methods: Patient leukocyte and neutrophil data after administration of docetaxel, paclitaxel, and etoposide were used to develop the model, which was also applied to myelosuppression data from 2'-deoxy-2'-methylidenecytidine (DMDC), irinotecan (CPT-11), and vinflunine administrations. The model consisted of a proliferating compartment that was sensitive to drugs, three transit compartments that represented maturation, and a compartment of circulating blood cells. Three system-related parameters were estimated: baseline, mean transit time, and a feedback parameter. Drug concentration-time profiles affected the proliferation of sensitive cells by either an inhibitory linear model or an inhibitory E(max) model. To evaluate the model, system-related parameters were fixed to the same values for all drugs, which were based on the results from the estimations, and only drug-specific parameters were estimated. All modeling was performed using NONMEM software.
Results: For all investigated drugs, the model successfully described myelosuppression. Consecutive courses and different schedules of administration were also well characterized. Similar system-related parameter estimates were obtained for the different drugs and also for leukocytes compared with neutrophils. In addition, when system-related parameters were fixed, the model well characterized chemotherapy-induced myelosuppression for the different drugs.
Conclusion: This model predicted myelosuppression after administration of one of several different chemotherapeutic drugs. In addition, with fixed system-related parameters to proposed values, and only drug-related parameters estimated, myelosuppression can be predicted. We propose that this model can be a useful tool in the development of anticancer drugs and therapies.
Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity.
Yan D, Ma X, Hu Y, Zhang G, Hu B, Xiang B Int J Nanomedicine. 2025; 20:2087-2101.
PMID: 39990288 PMC: 11844307. DOI: 10.2147/IJN.S500999.
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.
Agema B, Koch B, Mathijssen R, Koolen S Drugs. 2025; .
PMID: 39939511 DOI: 10.1007/s40265-025-02152-6.
Park H, Mugundu G, Singh A Clin Transl Sci. 2025; 18(2):e70146.
PMID: 39936636 PMC: 11815715. DOI: 10.1111/cts.70146.
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies.
Lefevre A, Parra-Guillen Z, Troconiz I, Boetsch C, Frances N Front Immunol. 2025; 15:1463915.
PMID: 39896804 PMC: 11782561. DOI: 10.3389/fimmu.2024.1463915.
Zhang L, Xu P, Yan X ACS Pharmacol Transl Sci. 2025; 8(1):189-202.
PMID: 39816799 PMC: 11729431. DOI: 10.1021/acsptsci.4c00575.